reporter gene (PstBst:pTKCAT) expression in ␤-cell lines, suggesting that both sites have a role in pdx-1 expression. However, they both were not absolutely essential, since the double mutant was as active as single mutants (15) . Three HNF3 proteins (␣, ␤, and ␥) are actually found in islet ␤ cells (53) . However, since antisera that specifically recognize HNF3␤ quantitatively shifted the HNF3 site gel shift complex, HNF3␤ is believed to be the activator (15, 29, 60) . Unfortunately, a direct role for HNF3␤ in pdx-1 transcription in vivo cannot be assessed in hnf3␤ Ϫ/Ϫ mice because of early embryonic lethality (3, 57) . However, a decrease in pdx-1 mRNA levels observed in embryoid bodies from hnf3␤ Ϫ/Ϫ embryonic stem cells supports a role for HNF3␤ in pdx-1 transcription in vivo (15) .
In the present study, we examined by transgenic analysis the activity of the individual area I and area II subdomains and the effect of the mutation in the area II HNF3 site on PB hsplacZ expression. In addition, cultured cell lines were used to identify regulators of area II. Area II hsplacZ expression was observed in islet ␤ cells but only in a subfraction of those expressing PDX-1. The area II HNF3 binding site mutant of PB hsplacZ was also only detected in a subfraction of the ␤-cell population. In contrast, the area I-driven transgene had no islet activity. Analysis of a series of individual area II block mutants in transfected ␤-cell lines defined a number of other potential positive-and negative-acting control elements. Pax6 was shown to be capable of specifically binding to an area II control element that is involved in transcriptional activation. Chromatin immunoprecipitation (ChIP) assays performed on the area II region demonstrated that Pax6 and HNF3␤ also bind in vivo . Thus, our data imply that area II plays a principal role in regulating pdx-1 expression in ␤ cells, in part through the actions of Pax6 and HNF3␤.
MATERIALS AND METHODS
pdx-1 transgene constructs and generation of transgenic mice. Human area I (bp Ϫ2839 to Ϫ2520) and area II (bp Ϫ2141 to Ϫ1890) sequences were PCR amplified, and transgenes were constructed as previously described (60) . The area II HNF3␤ binding site mutant transgene was created by subcloning PstBst m5 sequences from PstBst:pTK m5 into the transgene vector. The constructs were confirmed by restriction mapping and by partial sequence analysis. Transgenic lines were subsequently generated for each construct as previously described (60) .
Genotyping. Adults were genotyped by PCR with nested primers for lacZ. DNA from neonatal brain tissue or adult tails was prepared and analyzed as described previously (21) . Southern blotting was performed with PvuII-digested genomic DNA and a 726-bp PvuII lacZ fragment as a probe to estimate the transgene copy number in each line.
Detection of ␤-Gal. Abdominal organs and pancreata from 1-to 2-day-old pups were dissected and placed in phosphate-buffered saline on ice. Tissues were stained for ␤-galactosidase (␤-Gal) activity and then paraffin embedded as previously described (60) . Serial 7-m sections were mounted on glass slides for immunohistochemical analysis.
Immunohistochemistry. The Vectastain ABC (Vector Laboratories) and Histomouse SP (Zymed Lab-SA System; Zymed Laboratories, Inc.) kits were used for glucagon and insulin immunohistochemical staining, respectively. The guinea pig antibovine insulin serum (Linco) and rabbit antiglucagon serum (Linco) were used at a 1:1,000 dilution. Immunoperoxidase activity was detected by incubation with diaminobenzidine-H 2 O 2 substrate (Vector Laboratories).
Transfection constructs. The area II and PstBst reporter constructs were made by using human sequence from bp Ϫ2141 to Ϫ1961) and mouse (Pst/Ϫ2917bp:Bst/ Ϫ1890bp [60] ) pdx-1 sequences, which were cloned directly upstream of the herpes simplex virus thymidine kinase (TK) promoter in the chloramphenicol acetyltransferase (CAT) vector, pTK(An) (23) . Block transversion and single base mutations were created in area II:pTK and PstBst:pTK by using the QuickChange mutagenesis kit (Stratagene). Mutagenesis primers were designed according to the kit protocol. The human Ϫ2141/Ϫ1961 sequence was generated by the PCR and cloned into pTK(An). All construct sequences were confirmed by DNA sequencing.
Cell transfections.
Monolayer cultures of the pancreatic islet ␤-cell (␤TC-3, HIT-T15, and INS-1) and non-␤-cell (BHK, HeLa, H4IIE, and NIH 3T3) lines were maintained as described previously (59) . Rous sarcoma virus (RSV) enhancer-driven luciferase (LUC) activity from pRSVLUC was used to normalize CAT activity in each transfection. HIT-T15 and BHK cells were transfected by the calcium phosphate coprecipitation procedure (10 g, total DNA) with 1 g of area II:pTK and pRSVLUC and treated 4 h after addition of the DNA precipitates with 20% glycerol for 2 min. The Lipofectamine reagent (Gibco-BRL) was used to transfect 1 g each of area II or PstBst:pTK and pRSVLUC into ␤TC-3 and INS-1 cells. Extracts were prepared 40 to 48 h after transfection, and LUC (9) and CAT (31) enzymatic assays were performed. Each experiment was carried out at least three independent times.
Electrophoretic mobility shift assays. Nuclear extract from cell lines (38) and human islets (6) were prepared as described previously. The area II block 8 sequence (bp Ϫ2072 to Ϫ2054) was excised from Ϫ2072/Ϫ2054:pBluescript and Klenow labeled with [␣-
32 P]dATP. Binding reactions (20 l, total volume) were conducted with 5 to 10 g of nuclear extract protein and probe to either bp Ϫ2072 to Ϫ2054 or P6Con, a consensus Pax6 binding element (8 ϫ 10 4 cpm) (12) . The conditions for the competition analyses were the same, except that a 50-to 100-fold excess of the specific competitor DNA was included in the mixture prior to addition of extract. The TNT-Coupled Reticulocyte Lysate system (Promega) was used to in vitro transcribe and translate Pax6 (pKW10-Pax6 [37] Ϫ2141 to Ϫ1952 probe (7.5 ϫ 10 4 cpm) was incubated with 50 g of nuclear extract in a buffer containing 10 mM Tris-HCl (pH 7.4), 50 mM NaCl, 1 mM EDTA, 25 g of poly(dA-dT), 10% glycerol, and 1 mM dithiothreitol (50 l, total). The DNA pellets were resuspended in loading buffer, heat denatured, and applied to a 6% DNA sequencing gel.
SDS-PAGE fractionation. ␤TC-3 nuclear extract (30 g) was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 10% polyacrylamide gel and then electrotransferred onto an Immobilon polyvinylidene difluoride membrane (Millipore). The ␤TC-3 extract lane was cut horizontally into 4-mm slices representing different molecular weight fractions as determined by comparison with colored Rainbow protein markers (Amersham). The proteins from each fraction were eluted and renatured as previously described (64) . Each fraction was analyzed for binding to the bp Ϫ2072 to Ϫ2054 probe.
ChIP assays. ␤TC-3 cells (ϳ0.5 ϫ 10 8 to 1.0 ϫ 10 8 ) were formaldehyde cross-linked, and the sonicated protein-DNA complexes were isolated under conditions described previously (16) . Pax6 (20 l; Covance) or HNF3␤ (15 l; Santa Cruz Biotechnology) antibody, normal rabbit immunoglobulin G (IgG; 10 g; Santa Cruz Biotechnology), or no antibody was added to the sonicated chromatin, followed by incubation for 1 h at 4°C. Antibody-protein-DNA complexes were isolated by incubation with A/G-agarose (Santa Cruz Biotechnology). PCR was performed on one-tenth of the purified, immunoprecipitated DNA by using Ready-to-Go PCR beads (Amersham Pharmacia Biotech) and 15 pmol of each primer. The primers used for amplification of mouse pdx-1 area II were Ϫ2208 (5Ј-GGTGGGAAATCCTTCCCTCAAG-3Ј) and Ϫ1927 (5Ј-CCTTAGG GATAGACCCCCTGC-3Ј). The primers used for amplification of mouse PEPCK (phosphoenolpyruvate carboxykinase) were Ϫ434 (5Ј-GAGTGACACC TCACAGCTGTGG-3Ј) and Ϫ96 (5Ј-GGCAGGCCTTTGGATCATAGCC-3Ј). The PCR products were confirmed by sequencing. Amplified products were electrophoresed through a 1.4% agarose gel in TAE buffer and visualized by ethidium bromide staining.
RESULTS
A sequence-conserved domain of the PstBst region imparts ␤-cell-selective activity in vivo. The PstBst transgene (PB hsplacZ ) spans conserved areas I and II and is expressed at high levels in the islet. To test whether these subdomains also and area II hsplacZ transgenic mice were generated. Twelve lines of area I transgenic mice and nine lines of area II transgenic mice were analyzed. None of the area I hsplacZ mice expressed ␤-Gal in the pancreas (data not shown). In contrast, pancreas expression was observed in seven of the nine area II hsplacZ lines, with ␤-Gal activity principally limited to islet ␤ cells (Fig.  1) . Each of the area II hsplacZ lines gave a similar expression pattern in the pancreas that was independent of transgene copy number (one to five copies/line) or chromosomal integration site. However, extrapancreatic staining varied between lines, presumably reflecting regulation imposed by nonrelated sequences at the integration site.
Area II-driven transgene expression was detected in a subfraction of the islet cells and primarily in the insulin-producing cell population (Fig. 1) . In comparison to PB hsplacZ (see Fig.  2A ), the limited expression of the area II transgene within islet ␤ cells presumably reflects the loss of critical regulatory contributions by non-area II sequences within the PstBst region. Nonetheless, these results directly demonstrate that area II contains control elements sufficient for islet ␤-cell-selective transcription of pdx-1.
Mutation of the HNF3 element in area II affects PB hsplacZ activity in vivo. Mutational and functional analysis of the conserved HNF3 binding sites located within area I and area II demonstrated that a large fraction of the PstBst region activity in transfected ␤ cells was dependent upon it (15, 29, 60) . To determine the importance of HNF3 function, a mutation that selectively eliminated binding in area II was incorporated into PB hsplacZ (15, 60) . Five independent transgenic lines of the area II HNF3 binding site mutant PB hsplacZ were generated, of which three yielded an islet cell-specific expression pattern. The remaining two showed no activity possibly due to integration into transcriptionally inactive chromatin. The ␤-Gal expression in the HNF3 binding site mutant was compared to islets from PB hsplacZ . Insulin and glucagon immunohistochemical analysis demonstrated that ␤-Gal activity from the PB hsplacZ HNF3 mutant was primarily found in islet cells (Fig. 2) . Because HNF3 is expressed in all islet cells (60), we expected to see a general decrease in ␤-Gal activity in the HNF3 site mutant relative to PB hsplacZ -expressing cells. Instead, we observed that the PB hsplacZ HNF3 mutant activity was confined to a subfraction of the ␤ cells.
The level of islet cell penetrance of the area II HNF3 site mutant PB hsplacZ and area II hsplacZ transgenes was compared. The fraction of expressing cells per islet ranged between 10 to 90% and 3 to 70% for the PB hsplacZ HNF3 site mutant and the area II hsplacZ mice, respectively (Fig. 3) . The lower level of expression in the area II hsplacZ mice suggests that area I factors are necessary for expression throughout the ␤-cell population. In addition, these and the above data suggest that the comprehensive islet expression of PB hsplacZ requires key cis-acting element(s) within area II.
Conserved area II sequences are important for ␤-cell activity. In transfection assays, area II reporter constructs containing either human or mouse sequence display ␤-cell-selective activity (15) . Conserved area II sequences appear to be the most important for activity, since the region of maximal identity between human and mouse sequence (bp Ϫ2141 to Ϫ1961, 80% identity; termed Core; (bp Ϫ2141 to Ϫ1890, 59% identity) in HIT-T15, ␤TC-3, and INS-1 ␤-cell lines (compare Core to area II; Fig. 4B ). To characterize the contribution of the conserved sequences to activity, each block (B1 to B17) of identity in human area II was independently mutated, and activity was measured in transfected ␤-cell lines (Fig. 4) . Mutations in B7, B8, and B13 affected (with B8 decreasing and B7 and B13 increasing) area II-driven activity in all ␤-cell lines used, whereas mutations in B2 to B5, B12, B14, B15, and B17 affected activity in only two of the three ␤-cell lines (Fig.  4B) . In contrast, the mutations in B1, B6, B9 to B11, and B16 had little effect on area II activation. The B8 site and a representative negative control site (i.e., B13) were mutated, and their activity was analyzed within the context of the area I-and area II-containing PstBst construct. The B8 and B13 mutations also affected PstBst stimulation (Fig. 4C) , since the B8 mutant activity was reduced by 50%, a level comparable to that of the HNF3␤ binding site mutants (15) , and the B13 mutation activity increased by 75%. We conclude that B8 (bp Ϫ2068 to Identification of potential area II transcription factor binding sites. To identify possible area II regulatory protein binding sites, DNase I footprinting analysis was performed over the region from bp Ϫ2141 to Ϫ1961 with ␤-cell (INS-1) and non-␤-cell (HeLa) nuclear extracts. The protected regions that were specific to the ␤-cell extract were presumed to represent cell-type-enriched DNA-binding activities. Using a labeled bottom-strand probe, five distinct sequence segments displayed ␤-cell-specific footprints. These included B7 and B8 (bp Ϫ2077 to Ϫ2051), B10 (bp Ϫ2048 to Ϫ2036), B11 and B12 (bp Ϫ2031 to Ϫ2019), B13 (bp Ϫ2016 to Ϫ2007), and B14 (bp Ϫ2006 to Ϫ1996) (Fig. 5) . The B14 footprint results from HNF3␤ binding (15, 29, 60) . The footprint observed with the area II topstrand probe was continuous over a large region extending from bp Ϫ2084 to Ϫ2036, spanning B6 to B10 (Fig. 5) . Highly similar digestion patterns were observed with ␤TC-3, HIT-T15, and Min6 nuclear extracts (data not shown). Because the B8 activator bound in a ␤-cell-selective fashion, the resulting studies focused on its identification.
Pax6 binds to the B8 activator element. The specificity of protein-DNA binding to a bp Ϫ2072 to Ϫ2054 B8 probe was determined by wild-type and mutant B8 competition in nuclear extracts prepared from ␤-cell lines (HIT-T15, ␤TC-3, and INS-1), human islets, and non-␤-cell lines (BHK [kidney], NIH 3T3, H4IIE [liver], and HeLa). A single, common protein-DNA complex was detected within ␤-cell and human islet extracts but not within the non-␤-cell extracts (Fig. 6A) . Furthermore, only the wild-type B8 competitor efficiently reduced the binding levels of this complex. However, the B8 block mutant competitor prevented formation of the ubiquitous complexes (indicated by asterisks in the figure), a finding consistent with the conclusion that they are unrelated to B8 activation. Together with the DNase I footprinting analysis, this experiment suggests that the B8 activator is a nuclear protein enriched in islet ␤ cells.
To characterize the B8 activator further, the molecular weight of the protein(s) binding to the bp Ϫ2072 to Ϫ2054 probe was estimated by separation and renaturation of ␤TC-3 nuclear proteins (Fig. 6B) . The major binding activity in fractions 6 and 7 comigrated with the principal B8 complex found in unfractionated ␤TC-3 extracts. The binding specificity of this complex corresponded to the B8 activator as binding was selectively eliminated by the wild-type competitor (data not shown). The molecular size range for fractions 6 and 7 (44 to 58 kDa) indicated that the B8 activator complex is composed of a protein(s) of roughly 50 kDa.
The molecular size of several ␤-cell-enriched transcription factors lies within this range, although no candidate was suggested by Transfac analysis (20) . We therefore determined directly whether in vitro-translated (IVT) forms of Hb9 (41 kDa [19] ), Nkx6.1 (44 to 46 kDa [26] ), Pax4 (38 kDa [22, 44] ), Pax6 (46.6 kDa [51] ), and PDX-1 (47 kDa [34; data not shown]) could bind to the B8 element. Each of these proteins was translated at similar levels in our reactions (Fig. 7A) . However, binding to the B8 probe was only observed with Pax6, and this complex comigrated with the complex detected in ␤TC-3 extracts (Fig. 7B) . Because Pax4 and Pax6 have similar binding properties (12, 27) , gel shifts were also conducted with a Pax6 consensus sequence probe (P6Con) that binds Pax4 with high affinity. As expected, both Pax4 and Pax6 bound effectively to the P6Con probe, but only Pax6 bound to B8 (Fig. 7C) . In addition, preincubation of either IVT Pax6 or ␤TC-3 nuclear extract with monoclonal Pax6 antibody specifically eliminated B8 activator complex formation (Fig. 7D) .
The mouse B8 (mB8) element is 90% identical to the consensus sequence for the bipartite Pax6 paired DNA-binding domain (Fig. 8A) . As an additional test for the role of Pax6 in area II reporter gene activation, a single-base-pair binding mutation was created in this context. The G-to-T mutation in the mouse sequence (A to T in the human sequence) was chosen because it had been shown to specifically reduce Pax6 binding to the mouse glucagon G1 element (2). This mutation also prevented mB8 from competing for Pax6 binding in gel shift assays (compare Tmt to B8, Fig. 8B ). In addition, B8 Tmt decreased the activity of human area II by an amount similar to that caused by the B8 block mutation in transfection assays (Fig. 8C) . These results suggest that the binding of Pax6 to B8 regulates area II-mediated transcription. Pax6 and HNF3␤ bind to area II in vivo. To determine whether Pax6 and HNF3␤ bind within the area II region of the endogenous pdx-1, ChIP assays were carried out. The antibodies to Pax6 and HNF3␤ immunoprecipitated area II sequences from ␤TC-3 cells, in contrast to the rabbit IgG or the noantibody controls (Fig. 9 ). In addition, neither the Pax6 nor the HNF3␤ antibody immunoprecipitated the promoter sequences from the PEPCK gene, which is not transcribed in ␤TC-3 cells. The same results were obtained with chromatin from MIN6 ␤ cells (data not shown). These results are consistent with both Pax6 and HNF3␤ playing a central role in regulating the ␤-cell expression of pdx-1 in vivo .
DISCUSSION
PDX-1 is expressed in the progenitor cells of the endocrine and exocrine pancreas, primarily in the islet ␤ cells of the pancreas in adults. Cell-type-specific expression of PDX-1 is required for normal pancreas development and glucose homeostasis in mammals. In the present study, we examined the basis for ␤-cell-selective transcription of the pdx-1 gene. Previous analysis of 5Ј-flanking pdx-1 sequences suggested that cis-acting elements involved in tissue-specific transcriptional control were contained within conserved area I and area II sequences, since both of these domains are located within the PB hsplacZ transgene that is expressed primarily in islet ␤ cells in neonates (60) . The significance of area II was further demonstrated here. Area II and not area I independently targeted expression to islet ␤ cells in vivo; thus, this PstBst subdomain acts as a tissue-specific regulator. Mutation of the conserved HNF3 binding site in area II compromised islet cell expression of PB hsplacZ , indicating that HNF3␣, -␤, or -␥ had an essential role in the regulation of pdx-1 transcription . To localize additional regulatory elements within area II, blocks of conserved sequence within this subdomain were systematically mutated, and their effects on activation were determined in transfection assays. Several potential positive-and negative-acting control sites were identified, and Pax6, a factor involved in endodermal development and islet hormone gene expression, was shown to be associated with area II activation in vitro. Most significantly, our ability to detect Pax6 and HNF3␤ binding within the area II region of the endogenous pdx-1 gene provides additional support for a direct role in regulation.
Tissue-specific gene expression appears to be controlled by regulatory factors functioning in a cooperative manner. For example, specific positive-and negative-acting gene sequences control the elevation in ␣-fetoprotein expression in the fetal liver, the low levels in adults, and reexpression during liver FIG. 5 . DNase I footprinting reveals multiple ␤-cell-specific binding sites in area II. The human area II fragment extending from bp Ϫ2141 to Ϫ1961 was end labeled on the top or bottom strand and subjected to DNase I digestion after incubation with INS-1 or HeLa nuclear extracts (50 g). The DNase I-produced fragments were run along side Maxam-Gilbert sequencing reactions (G and GϩA) of the same fragment. Note the INS-1 selective protection pattern observed over B7 and B8 (bp Ϫ2077 to Ϫ2051), B10 (bp Ϫ2048 to Ϫ2036), B11 and B12 (bp Ϫ2031 to Ϫ2019), B13 (bp Ϫ2016 to Ϫ2007), and the HNF3␤ binding site (B14; bp Ϫ2006 to Ϫ1996) with the bottom-strand probe and over B6 through B10 with the top-strand probe.
FIG. 6.
A ␤-cell-specific protein binds to B8. (A) Nuclear extracts from ␤-cell (HIT-T15, ␤TC-3, and INS-1) and non-␤-cell (BHK, NIH 3T3, H4IIE, and HeLa) lines and human islets were analyzed for B8 binding in gel shift assays. A 100-fold molar excess of unlabeled wild type or block mutant B8 competitor to probe was used to distinguish the B8 activator complex from the nonspecific binding complexes. The arrow denotes the specific B8 binding activity, and the asterisks mark the nonspecific complexes. (B) ␤TC-3 nuclear extract was fractionated (see Materials and Methods) and assayed for specific B8 binding. Each fraction (i.e., fractions 1 to 14) represents a different molecular size range. A binding complex was detected in fractions 6 (44-kDa lower limit) and 7 (58-kDa upper limit) that comigrated with the ␤-cellenriched B8 binding complex in unfractionated ␤TC-3 nuclear extract. The arrow points to the ␤-cell-enriched binding complex. (45, 52, 58) . Similar to ␣-fetoprotein, pdx-1 is expressed in embryos throughout the pancreatic buds but is later downregulated in most exocrine cells and is primarily expressed in ␤ cells in the adult endocrine pancreas (32, 47) . In addition, expression is increased in response to partial pancreatectomy (62) . Thus, pdx-1 is expressed in a developmental and tissue-specific pattern that is also likely mediated by both positive-and negative-acting sequences. Specific positive-acting sequences have been demonstrated that drive transient ␤-cell-specific activity in the embryo and neonate but not in the adult (XhoBgl [13] ), whereas the islet cell-specific sequence is active at all ages (PstBst [13, 60] ). This independently acting, islet-specific regulatory segment was first identified in HSS1. Three subregions (i.e., areas I, II, and III) were identified within HSS1 for further study. Because the PstBst fragment spanning areas I and II drives tissue-specific trans- In a parallel study, area III conserved sequences were also tested by transgenic analysis (13) . Strikingly, only area II, but not area I (this report) or III (13), was capable of directing islet cellspecific transgene expression in neonatal mice. This implies that area II represents the principal islet control domain of PstBst and, presumably, also HSS1. Among the species studied, area II is only found within the mammalian pdx-1 genes (e.g., human, mouse, and rat [15; K. Gerrish and R. Stein, unpublished data]), implying that ␤-cell expression in unrelated species is driven by other non-area II sequences. Furthermore, the limited expression of the area II transgene to a fraction of islet cells indicates that functional interactions with non-area II transcription factors are critical for expression throughout the entire islet ␤-cell population. The factors that contribute to control include HNF3␤ in areas I (15, 29) (Fig. 9B) and II (15, 60) , PDX-1 (16, 29, 30) and HNF1␣ (16) by using ␤TC-3 nuclear extracts (␤TC-3 NE) or IVT Pax6. A 50-fold molar excess of unlabeled B8, B8 Tmt, and P6Con competitor was used. (C) Wild-type and mutant human area II:pTK constructs were transfected into ␤TC-3 and INS-1 cells. The ratio of mutant to wildtype area II:pTK activity is presented Ϯ the standard error. Note that the B8 block mutant (B8mt) and point mutant activities (B8 Tmt) are reduced to a similar level relative to the wild type. (Fig. 9B) . Importantly, pdx-1 mRNA expression is decreased 50 to 60% in ␤ cells upon conditional inactivation of the HNF3␤ gene by insulin-driven Cre recombinase expression in vivo (K. Kaestner, unpublished data). Together, these data indicate that HNF3␤ is an important regulator of pdx-1 transcription in the ␤ cell. Although it is unclear how HNF3␤ mediates transcriptional control, both the chromatin remodeling (17) and transcriptional activation potential (8) of this factor may be of significance. Since HNF3␤ (15, 60) and PDX-1 (18, 34) are essentially expressed within all islet ␤ cells, one expected outcome of mutating the area II HNF3␤ binding site would be a reduction in PB hsplacZ activity in all cells. In previous studies, the reduction in pdx-1 transcriptional activity in HNF3␤ binding site mutants in transfection assays and HNF3␤-null embryoid bodies was reported as a general reduction in expression (15) . These experiments evaluated the population of cells en masse, and any restriction to a subpopulation would have appeared as a reduction in expression. Thus, the apparent discrepancy with our results reflects the different assays used in these experiments. In the current study, the area II HNF3␤ binding site mutation did not appear to significantly reduce transgene activity within expressing cells as expected but instead limited activity to a fraction of the cells relative to wild-type PB hsplacZ ( Fig. 2 and 3) . Area II hsplacZ expression was similarly limited to a fraction of the ␤ cells ( Fig. 1 and 3) . It is unlikely that the sites of chromosomal integration or copy number influence these transgene expression patterns since very similar results were found in three independent PB hsplacZ HNF3␤ site mutant lines and in seven independent area II hsplacZ lines . The limited activity of the PB hsplacZ HNF3␤ site mutant and area II hsplacZ may reflect heterogeneity in expression and/or activity of cooperating transcriptional activators of the pdx-1 gene within the islet ␤-cell population. Evidence for functional heterogeneity among normal and transformed ␤ cells has been shown to exist at the metabolic level (4, 24, 36, 41) . The varied sensitivity to area II mutations seen in the HIT-T15, ␤TC-3, and INS-1 cell lines (Fig. 4) may, in addition, reflect heterogeneity in the transcriptional regulatory capacity among islet ␤ cells both in vitro and in vivo. Whether the restricted expression of the area II or PstBst mutant transgene denotes islet ␤ cells that also have different metabolic and/or neogenic potential is under investigation.
To begin to identify other factors that are necessary for area II activity, we prepared a comprehensive series of block mutations within the conserved sequences. Our transfection analyses demonstrated that no single mutation profoundly affected area II-mediated activation. Only 3 (B8, B7, and B13) of the 17 block mutants affected area II-mediated activation by ϳ50% or greater in our ␤-cell lines, with the mutation of B8 repressing activity and the mutation of B7 and B13 stimulating activity (Fig. 4) . The B8 and B13 mutations in PstBst recapitulated their effects in area II alone.
Our biochemical analysis focused on identifying the B8 activator. Pax6, a member of the paired-box, homeodomain transcription factor family was shown to specifically bind to B8 element sequences in vitro, and more significantly, to bind to area II sequences in vivo. Pax6 also appears to be involved in islet insulin, somatostatin, and glucagon gene activation (37) . These observations indicate that Pax6 is one component of a complex regulatory network involved in defining pdx-1 promoter activity in the pancreas.
Pax6 and Pax4 represent the only known members of the paired-box, homeodomain transcription factor family involved in pancreatic islet development (10) . Both of these proteins have similar in vitro DNA-binding properties (27) . Furthermore, Pax4 can inhibit insulin-and glucagon-driven reporter expression in transfected cells by competing for and reducing Pax6-mediated activation (35, 42) . As a consequence, competition between Pax4, which is expressed in the pancreas only during embryogenesis (42) , and Pax6 may be involved in regulating gene expression in islet progenitor cells. Pax6 and Pax4 gene ablation studies indicate that these factors also have distinct and nonoverlapping gene targets during islet cell development (44, 50) . The B8 element is different from many other Pax6 binding sites in not binding Pax4, implying a distinct role for Pax6 in pdx-1 transcription (Fig. 7) . Even though PDX-1 levels appear normal in Pax6 Ϫ/Ϫ embryos (37, 50), these animals die at birth (44, 50) due to central nervous system problems. Therefore, Pax6 may be required for normal pdx-1 expression and islet function at later points. Several mouse models of islet neogenesis also support a function for Pax6 in pdx-1 expression (28, 43, 61) .
The ability of area II, but not of area I, to direct ␤-cellspecific transgene expression indicates that the transcription factors important for its activation are also essential in making the pdx-1 gene locus competent for transcription. In general, little is known about the mechanisms utilized to convert a silent gene to a transcriptionally active one. With analogy to the manner in which HNF3␤ functions in albumin gene activation (7), we presume that the earliest regulators bind within area II to initiate opening of the chromatin and transcription complex assembly prior to pdx-1 gene activation. The limited islet ␤-cell expression pattern observed for the PB hsplacZ area II HNF3␤ binding site mutant supports the proposal that HNF3␤ may serve in this capacity for pdx-1. However, detection of pdx-1 expression in HNF3␤ Ϫ/Ϫ embryoid bodies (15) indicates that other factors are also important in nucleating transcription complex assembly. Initiation of Pax6 expression occurs later than that of pdx-1, suggesting that Pax6 represents a factor that is recruited to transcriptionally active chromatin to modulate activity. Our area II mutational studies and DNase I footprinting have defined potential binding sites for factors that may act in conjunction with Pax6 and HNF3␤ to mediate tissue-specific control of the pdx-1 gene. We believe that identifying these regulatory factors will not only provide insight into the mechanisms involved in regulating pdx-1 transcription and pancreas development but also may help to identify heritable defects that cause insulin deficiency and diabetes.
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